Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $7.84M, compared with -$1.15M a year earlier. Trailing-twelve-month accounts receivables was -$51.06M. Over 3 fiscal years it compounded at +77.2% a year.

Context

  • Accounts receivables amounted to 14.9% of revenue in FY2025, up 5.4 pp from a year earlier.
  • Accounts receivables grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $7.84M or moves back toward the trailing-twelve-month quarterly average of -$12.76M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.84M+137.0% QoQ
Last fiscal yearDec 2025
-$60.05M+89.7% YoY
LTMMar 2026
-$51.06M+91.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+780.4%——
1 year+89.7%——
3-year CAGR+77.2%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(60.05M) USD
Year-over-year change
-89.7%

Accounts Receivables vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +91.4% is the 7th highest of 8, against a peer median of +207.1%.
  • Accounts receivables amounts to 12.2% of revenue for ESPR, versus a peer median of 7.3%.
ESPR Competitors
Accounts Receivables for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$59.9M USD+225.6%-40.0%8.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$51.06M USD+91.4%+77.2%12.2%
RGNXREGENXBIO Inc.LTM Mar 2026$9.02M USD+328.9%—10.3%
OFIXOrthofix Medical Inc.LTM Mar 2026$5.26M USD+166.0%-38.3%0.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$3.65M USD+482.9%—7.3%
SIGASIGA Technologies, Inc.LTM Mar 2026$2.68M USD-75.5%-22.4%2.9%
ABSIAbsci CorporationLTM Mar 2026$1.38M USD+207.1%—75.4%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$36K USD+167.9%——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
SNDLSNDL Inc.LTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding ESPR) —+207.1%-38.3%7.3%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Depreciation & Amortization612K500K164K63K105K
Deferred Income Tax00000
Stock-Based Compensation24.31M15.22M11.96M11.99M9.87M
Change in Working Capital(52.51M)(3.37M)13.68M(60.53M)(14.64M)
Accounts Receivables(10.55M)(10.8M)(14.77M)(31.65M)(60.05M)
Inventory(18.26M)(807K)(30.42M)(28.87M)(10.63M)
Accounts Payables(34.1M)5.6M8.68M12.43M20.92M
Other Working Capital10.39M2.63M50.18M(12.45M)35.12M
Other Non-Cash Items32.89M46.49M47.96M76.57M14.26M
Operating Cash Flow(263.81M)(174.83M)(135.49M)(23.65M)(13.09M)
Capital Expenditures000(317K)0
Acquisitions (Net)00000
Purchases of Investments(50.48M)(59.9M)000
Sales of Investments068M42.5M00
Other Investing Activities00000
Investing Cash Flow(50.48M)8.1M42.5M(317K)0
Debt Repayment(440K)(58.24M)(15.51M)35.01M(54.91M)
Common Stock Issued218.69M90.85M56.88M91.19M98.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities49.98M0(6.42M)(39.72M)(7.26M)
Financing Cash Flow268.22M32.61M50.46M86.48M36.18M
Effect of Forex Changes00000
Net Change in Cash(46.07M)(134.12M)(42.53M)62.51M23.09M
Free Cash Flow(263.81M)(174.83M)(135.49M)(23.97M)(13.09M)

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.